Has Mayank Sardana, MD received payments from drug or device companies?

Yes. Drug and device makers reported $36,489 in general payments to Mayank Sardana, MD across 87 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mayank Sardana, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mayank Sardana, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mayank Sardana, MD

Cardiovascular Disease · Scottsdale, AZNPI 1922363035

Payments from drug & device makers

What this record shows

This record is dominated by grants: $25,901 of the $36,489 with a category attached, or 71.0%. Medtronic accounts for 73.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $28,334 and has fallen 98.9% since, to $313 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,489in general payments, 2019–2025

Across 87 payments — averaging $419.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$27K
Abbott$3K
Boston Scientific$2K
Haemonetics Corporation$2K
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$685
Acutus Medical, Inc.$477
plus $2K from 8 others

What the payments were for

Consulting fees$5001%
Grants$25,90171%
Travel & lodging$4,36512%
Food & beverage$5,00514%
Education$6942%
Entertainment$240%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	21	$26,655
Abbott	28	$3,195
Boston Scientific	8	$2,082
Haemonetics Corporation	2	$1,888
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	9	$685
Acutus Medical, Inc.	3	$477
Biotronik Inc.	2	$450
Atricure, Inc.	2	$312
Biosense Webster, Inc.	3	$270
Impulse Dynamics (USA) Inc.	2	$242
Medical Device Business Services, Inc.	3	$137
Bardy Diagnostics, Inc.	2	$47
Amgen	1	$27
Kestra Medical Technology Services, Inc.	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AVEIR$1,952
GENERAL TACHY$901
GENERAL - THERAPIES$776
EVERA MRI XT DR SURESCAN$544
OPTIMIZER$360
EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$312
LifeVest$266
Carto 3$253
Confirm Rx$249
Ensite Cardiac Mapping System$244
Micra$183
CARDIOMEMS$179
Azure$163
ENSITE PRECISION$115
WATCHMAN Access System$110
Assurity Pacemaker$103

How this compares

$36,489 in reported general payments places this provider in the 90th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona →

Medicare billing

Part B allowed, 2024

$343,734

Medicare patients

2,945

Services billed

5,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	26	$33,988
Flecainide Acetate	22	$663
Amiodarone Hcl	25	$504
Metoprolol Succinate	24	$321
Metoprolol Tartrate	11	$68
Carvedilol	11	$58

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Scottsdale

Krishnaswami VijayaraghavanScottsdale$927K
Paul UnderwoodScottsdale$259K
Robert BurkeScottsdale$207K
David RizikScottsdale$128K
Martin CerdaScottsdale$66K
Pattara RattanawongScottsdale$43K
Ashish GuptaPhoenix$1.1M
Rajkumar SugumaranPhoenix$957K
Steven MottlTucson$340K
Omar WaniFlagstaff$244K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →